Sildenafil citrate is a small molecule commercialized by Dare Bioscience, with a leading Phase II program in Female Hypoactive Sexual Desire Disorder. According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Sildenafil citrate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Sildenafil citrate is expected to reach an annual total of $42 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Sildenafil citrate Overview

Sildenafil citrate (SST-6007) is under development for the treatment of female hypoactive sexual desire disorder. The drug candidate is a small molecule applied vaginally and topically to the female genitalia. It acts by targeting phosphodiesterase 5 (PDE-5). It is developed based on KNOSIS delivery technology.

Dare Bioscience Overview

Dare Bioscience is a biopharmaceutical company that develops products for women’s reproductive health. Its product pipeline includes Ovaprene, an investigational hormone-free monthly intravaginal contraceptive designed to be worn conveniently over multiple weeks, Sildenafil a phosphodiesterase-5 (PDE-5) inhibitor and XACIATO for the treatment of of bacterial vaginosis in females 12 years of age and older. Dare Bioscience‘s also provides DARE-PDMI, DARE-PDMI, DARE VVA1, DARE FRTI/PTBI, DARE-LARC1 and DARE-RH1, among others. The company develops and markets therapies for women in the areas of contraception, vaginal health, sexual health and fertility. Dare Bioscience is headquartered in San Diego, California, the US.

For a complete picture of Sildenafil citrate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.